埃索美拉唑三联与奥美拉唑三联治疗HP阳性十二指肠溃疡的临床对比研究被引量：8

在线阅读下载PDF

导出

摘要目的:比较埃索美拉唑三联与奥美拉唑三联治疗幽门螺杆菌(HP)阳性十二指肠溃疡的临床疗效。方法:将82例HP阳性的十二指肠溃疡患者随机分为2组,EAC组(埃索美拉唑+阿莫西林+克拉霉素)和OAC组(奥美拉唑+阿莫西林+克拉霉素),EAC组41例,OAC组41例,疗程2周。4周后复查胃镜并检测HP,观察溃疡愈合率、HP根除率及临床症状缓解情况等。结果:EAC组前3d临床症状(包括腹痛、反酸、烧心等)缓解率明显高于OAC组,差异有统计学意义(P<0.05),3d后临床症状缓解率比较,两组差异无统计学意义(P>0.05)。EAC组和OAC组治疗后溃疡愈合率及HP根除率比较,差异无统计学意义(P>0.05)。结论:埃索美拉唑三联治疗HP阳性的十二指肠溃疡的临床症状缓解速度优于奥美拉唑三联治疗。

作者颜开华朱明艳胡林孙振兴

机构地区张家港澳洋医院消化内科

出处《中国医药导报》 CAS 2008年第34期46-47,共2页 China Medical Herald

关键词十二指肠溃疡幽门螺杆菌埃索美拉唑奥美拉唑

分类号 R573.1 [医药卫生—消化系统]

引文网络
相关文献

参考文献7

1顾同进,竺越.质子泵抑制剂族的新药——埃索美拉唑[J].中国临床药学杂志,2006,15(2):73-75. 被引量：17
2张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民.幽门螺杆菌若干临床方面的共识意见(2003·安徽桐城)[J].中华内科杂志,2004,43(4):316-317. 被引量：140
3胡伏莲.幽门螺杆菌感染与上胃肠道疾病[J].临床内科杂志,2003,20(2):57-59. 被引量：12
4[4]Malfertheiner P,Megraud F,O'Morain C,et al.Current concepts in the management of helicobacter priori infection:the maastricht Ⅲ consensus report[J].Gut,2007,56(6):772-781.
5张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民.幽门螺杆菌共识意见(2003·安徽桐城)[J].中华消化杂志,2004,24(2):126-127. 被引量：439
6[6]Castell DO,Kahrilas PJ,Richter JE,et al.Esomeprazole(40mg)compared with lansoprazole930(mg)in the treatment of erosive esophagitis[J].Am J Gastroeterol,2002,9:575-583.
7[7]Talley NJ,Lauritsen K,Tunturi-Hihnala H,et al.Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease:a controlled trial of "on-demand"therapy for 6 months[J].Aliment Pharmacol Ther,2001,15:347-354.

二级参考文献29

1湛先保,李兆申,程能能,杜奕奇,邹多武,尹宁,龚燕芳.埃索美拉唑对健康志愿者抑制胃泌酸的药效学研究[J].中华消化杂志,2004,24(12):711-714. 被引量：21
2胡伏莲,黄志烈,王菊梅,贾博琦,刘新光,谢鹏雁.幽门螺杆菌的根除及其在十二指肠溃疡愈合和复发中的作用[J].中华消化杂志,1996,16(2):106-107. 被引量：109
3[2]International agency for research on cancer. Schitosomes, live flukes and helicobacter pylori. IARC monographs on the evaluation on carcinogenic risks to humans. Vol61, Lyon:IARC,1994.
4[4]Correa P. A human model of gastric carcinogenesis. Cancer Res, 1988, 48:3554-3560.
5[7]Parsonnet J.Helicobacter pylori and gastric ulcer. Gastroenterol Clin North Am,1993,22:89-.
6[9]Genta RM, Hamner HW, Graham DY. Gastric lymphoid ollicles in Helicobacter pylori infection: frequency, distribution and response to triple therapy. Hum Pathol 1993,24: 577-583.
7[10]Wotherspoon AC, Doglioni C, Diss TC, et al.Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet ,1993, 342:575-577.
8Malfertheiner P, Megraud F, O′Morain C, et al. European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther,2002 ,16:167-180.
9Malfertheiner P, Megraud F, O'Morain C, et al. European Helicobacter Pylori Study Group(EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther, 2002,16:167-180.
10Hammer J,Schmidt B.Effect of Splitting the dose of esomeprazole on gastric acidity and noctumal acid break through[J].Aliment pharmocol ther,2004,19(10):1105.